What is Xcovery?
Xcovery is dedicated to advancing oncology therapies through cutting-edge science, aiming to develop treatments that are not only more effective but also less toxic and more tolerable for patients. The company's mission is to expedite the transition of life-changing agents from research to clinical application, thereby enhancing the quality of life for individuals courageously battling cancer and empowering the oncology community with superior tools for patient care. Their focus on innovation in cancer treatment positions them as a key player in the biopharmaceutical industry.
How much funding has Xcovery raised?
Xcovery has raised a total of $48.9M across 8 funding rounds:
Series A
$2.4M
Series B
$6M
Debt
$2.1M
Multiple Rounds
$38.1M
Debt
$350K
Series A (2011): $2.4M, investors not publicly disclosed
Series B (2012): $6M, investors not publicly disclosed
Debt (2013): $2.1M, investors not publicly disclosed
Series C (2014): $2.4M, investors not publicly disclosed
Series D (2014): $15M backed by EMS S/A and Brace Pharma
Debt (2014): $675K, investors not publicly disclosed
Private Equity (2014): $20M led by Betta Pharmaceuticals
Debt (2020): $350K supported by PPP
Key Investors in Xcovery
Betta Pharmaceuticals
Betta Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company focused on developing and commercializing innovative oncology products. They have a strong track record in bringing targeted therapies for non-small cell lung cancer to market.
EMS S/A
EMS Pharma, headquartered in Brazil, is a domestic pharmaceutical company established in 1950, serving as a significant distributor of pharmaceuticals within the Brazilian market.
Brace Pharma
Brace Pharma Capital is an investment firm specializing in innovative therapies for diseases with significant unmet medical needs, aiming to support the development of life-changing medicines.
What's next for Xcovery?
With substantial enterprise-level backing, Xcovery is poised for accelerated expansion and the advancement of its oncology pipeline. The strategic investment will likely fuel further research and development, clinical trials, and potential commercialization efforts. This infusion of capital signals confidence from investors in Xcovery's scientific approach and its potential to address unmet needs in cancer therapy, paving the way for future growth and market penetration.
See full Xcovery company page
